Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 4/20 | 1.00 |
| ▸ | LDHB | P07195 | 4/20 | 1.00 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | PTPN22 | Q9Y2R2 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343475 | 1.00 | LDHA (1.00) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL1435328 | 0.88 | LDHA (0.78) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL2556095 | 0.84 | LDHA (0.72) | LDHALDHBHAO1KDM4ETDP1 | |
| SCHEMBL2553518 | 0.84 | LDHA (0.72) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL31074043 | 0.83 | LDHA (0.71) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL6386971 | 0.83 | LDHA (0.71) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL38654969 | 0.82 | LDHA (0.69) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL38654659 | 0.82 | LDHA (0.69) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL31358706 | 0.82 | LDHA (0.68) | LDHALDHBHAO1AKT1KDM4E | |
| SCHEMBL15331986 | 0.81 | LDHA (0.68) | LDHALDHBHAO1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026741-A1 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-01-23 | — | — | US | disclosed |
| WO-2023091674-A1 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | UNIV GRANADA (ES) | 2020-06-25 | — | — | US | disclosed |
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | UNIV GRANADA (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| EP-1802297-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| EP-1802297-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | BURNHAM INST (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1802297-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | The Burnham Institute (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006047162-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | THE BURNHAM INSTITUTE (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197418-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY OXALATE ACCUMULATION | DOHH, OGDH, EGLN2 | LDHA 281/4885LDHB 408/4885HAO1 86/4885 |
| US-20250026741-A1 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | PTPN18, PTPN7, PTPN1 | LDHA 4155/4885LDHB 4000/4885HAO1 1791/4885 |
| US-20090312352-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE CAUSED BY YERSINIA SPP INFECTION | PTPRS, PTPRO, PTPN5 | LDHA 3091/4885LDHB 2857/4885HAO1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.